阶段角度作为非计划性ICU重置风险的潜在预测因素在重症手术患者:一个回顾性队列研究
Minseob Kim1,2, Hye Young Woo1,2,3, Christine Kang1
1Department of Critical Care Medicine, Seoul National University Hospital, Seoul, South Korea.
International journal of surgery (London, England)
|February 24, 2026
概括
在ICU入院时测量的相角 (PhA) 是重症监护室重入院的强有力的预测指标. 这种细胞完整性的非侵入性标志物为患者的结果提供了有价值的预后信息.
科学领域:
- 临界护理医学 临界护理医学
- 生物阻抗分析分析
- 外科手术的结果
背景情况:
- 外科重症监护室 (ICU) 的再接收与患者的不良结果有关.
- 预测ICU再入院是当前临床指数具有挑战性的.
- 阶段角 (PhA) 是一种生物阻抗衍生标记,反映细胞完整性和营养状况.
研究的目的:
- 调查相角 (PhA) 的预后值,用于预测手术ICU再入院.
- 为了确定在ICU入院和出院时的PhA测量是否能比现有方法更好地预测再入院.
主要方法:
- 一项对510名外科重症监护室出院者的回顾性队列研究.
- 阶段角 (PhA) 通过生物电阻分析在ICU入院 (PhA0) 和放电 (PhAdc) 时测量.
- 用于初级分析的混合效应逻辑回归,每位患者多次出院.
主要成果:
- 不规划的ICU再入院发生在13.3%的出院者中 (68/510).
- 在ICU入院时低PhA (PhA0) 独立预测的再入院 (aOR=4.00,P<0.001).
- 出院时的低PhA (PhAdc) 显示出预测再入院的趋势 (aOR=1.80,P=0.07);紧急手术也与此相关.
结论:
- 在ICU入院时测量的相角 (PhA) 是手术ICU再入院的可操作,非侵入性预后指标.
- PhA测量可以提高手术ICU患者的风险分层.
- 利用PhA可能有助于制定有针对性的干预措施,以降低再接收率.
更多相关视频
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
2.9K
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
687
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
01:12Hazard Ratio
785
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
785